Improved visual outcome with early treatment in macular edema secondary to retinal vein occlusions: 6-month results of a Korean RVO study

被引:17
|
作者
Yoon, Young Hee [1 ]
Kim, Ha Kyoung [2 ]
Yoon, Hee Seong [3 ]
Kang, Se Woong [4 ]
Kim, June-Gone [1 ]
Park, Kyu Hyung [5 ]
Jo, Young Joon [6 ]
Lee, Joo Yong [1 ]
Lee, Dong Hoon [1 ]
机构
[1] Univ Ulsan, Dept Ophthalmol, Asan Med Ctr, Seoul 138736, South Korea
[2] Hallym Univ, Dept Ophthalmol, Kangnam Sacred Heart Hosp, Seoul, South Korea
[3] St Marys Eye Clin, Pusan, South Korea
[4] Sungkyunkwan Univ, Dept Ophthalmol, Samsung Med Ctr, Seoul, South Korea
[5] Seoul Natl Univ, Dept Ophthalmol, Bundang Hosp, Gyeonggi Do, South Korea
[6] Chungnam Natl Univ Hosp, Dept Ophthalmol, Taejon, South Korea
关键词
Retinal vein occlusion; Macular edema; Duration of symptom; Early treatment; Korean patients; INTRAVITREAL TRIAMCINOLONE; STANDARD-CARE; RISK-FACTORS; BRANCH; EFFICACY; SAFETY;
D O I
10.1007/s10384-014-0305-9
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
To determine the correlation between the duration of macular edema (ME) and visual outcomes among Korean patients with retinal vein occlusion (RVO). Multicenter, interventional case series. Treatment-naive patients (n = 249) with branch or central RVO (BRVO/CRVO) and ME for < 6 months were included. We assessed the correlation between the duration of ME and treatment outcomes including the mean logarithm of the minimum angle of resolution best-corrected visual acuity (logMAR BCVA) improvement, the proportion of patients achieving at least a 3-line gain in BCVA, and the mean reduction in central retinal thickness (CRT) at 6 months. One hundred and fifty-six patients with BRVO and 93 patients with CRVO were divided into five groups based on the duration of ME (< 2, 2-4 weeks, 1-2, 2-3, 3-6 months); the mean baseline BCVA and CRT among the groups did not differ significantly. In BRVO, the mean logarithm of the minimum angle of resolution (logMAR) BCVA improvements in the groups were 0.51, 0.32, 0.17, 0.19, and 0.13, respectively (P = 0.002). The respective percentages of at least 3-line gains were 64, 53, 39, 38, and 21 % (P < 0.001). The BCVA didn't significantly improve in CRVO. The decrease in CRT was not correlated significantly with the duration of ME in either disease. Treatment of BRVO as early as 2 weeks after onset of ME enhanced the visual outcome; there was no correlation in the patients with CRVO. This finding supports the current trend favoring early treatment to obtain better visual outcomes in patients with BRVO.
引用
收藏
页码:146 / 154
页数:9
相关论文
共 50 条
  • [41] Efficacy and safety of ranibizumab 0.5 mg in Asian patients with visual impairment due to macular edema secondary to branch retinal vein occlusion: results from the 12-month BLOSSOM study
    Wei, Wenbin
    Zhu, Liansheng
    Weisberger, Annemarie
    Cheng, Yu
    Liu, Chang
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2017, 58 (08)
  • [42] Predictors for very Long time visual outcome in macular edema secondary to retinal vein occlusion treated in real-world setting
    Rehak, Matus
    Busch, Catharina
    Lamprecht, Pia-Sophie
    Wiedemann, Peter M. H.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2018, 59 (09)
  • [43] Comparison of ranibizumab with or without focal/grid laser for macular edema secondary to branch retinal vein occlusion: 12-month results from the ZIPANGU study
    Murata, Toshinori
    Kondo, Mineo
    Inoue, Makoto
    Nakao, Shintaro
    Osaka, Rie
    Shiragami, Chieko
    Sogawa, Kenji
    Mochizuki, Akikazu
    Shiraga, Rumiko
    Ohashi, Yohei
    Kaneko, Takeumi
    Tsujikawa, Akitaka
    Kamei, Motohiro
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2020, 61 (07)
  • [44] Real-World Management of Macular Edema Secondary to Retinal Vein Occlusion with Intravitreal Aflibercept: 24-month Results from the AURIGA Observational Study
    Giocanti-Auregan, Audrey
    Donati, Simone
    Hoerauf, Hans
    Allmeier, Helmut
    Rittenhouse, Kay D.
    Machewitz, Tobias
    Yang, Chang-Hao
    OPHTHALMOLOGY AND THERAPY, 2024, 13 (01) : 179 - 203
  • [45] Real-World Management of Macular Edema Secondary to Retinal Vein Occlusion with Intravitreal Aflibercept: 24-month Results from the AURIGA Observational Study
    Audrey Giocanti-Aurégan
    Simone Donati
    Hans Hoerauf
    Helmut Allmeier
    Kay D. Rittenhouse
    Tobias Machewitz
    Chang-Hao Yang
    Ophthalmology and Therapy, 2024, 13 : 179 - 203
  • [46] Three Monthly Injections Versus One Initial Injection of Ranibizumab for the Treatment of Macular Edema Secondary to Branch Retinal Vein Occlusion: 12-Month Results of a Prospective Randomized Study
    Tang, Wenyi
    Guo, Jingli
    Xu, Gezhi
    Liu, Wei
    Chang, Qing
    OPHTHALMOLOGY AND THERAPY, 2022, 11 (06) : 2309 - 2320
  • [47] Three Monthly Injections Versus One Initial Injection of Ranibizumab for the Treatment of Macular Edema Secondary to Branch Retinal Vein Occlusion: 12-Month Results of a Prospective Randomized Study
    Wenyi Tang
    Jingli Guo
    Gezhi Xu
    Wei Liu
    Qing Chang
    Ophthalmology and Therapy, 2022, 11 : 2309 - 2320
  • [48] Twenty-four month results of intravitreal ranibizumab for macular edema after branch retinal vein occlusion in a single-center prospective study: visual prognosis and rate of complete resolution of macular edema
    Inagaki, Miho
    Hirano, Yoshio
    Suzuki, Norihiro
    Yasuda, Yusuke
    Kawamura, Mihoko
    Yasukawa, Tsutomu
    Yoshida, Munenori
    Ogura, Yuichiro
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2019, 60 (09)
  • [49] Sustained Benefits from Ranibizumab for Central Retinal Vein Occlusion with Macular Edema: 24-Month Results of the CRYSTAL Study
    Larsen, Michael
    Waldstein, Sebastian M.
    Priglinger, Siegfried
    Hykin, Philip
    Barnes, Elizabeth
    Gekkieva, Margarita
    Das Gupta, Ayan
    Wenzel, Andreas
    Mones, Jordi
    OPHTHALMOLOGY RETINA, 2018, 2 (02): : 134 - 142
  • [50] Benefit from Bevacizumab for Macular Edema in Central Retinal Vein Occlusion: Twelve-Month Results of a Prospective, Randomized Study
    Epstein, David L.
    Algvere, Peep V.
    von Wendt, Gunvor
    Seregard, Stefan
    Kvanta, Anders
    OPHTHALMOLOGY, 2012, 119 (12) : 2587 - 2591